If you've worked with recombinant proteins for immunoassay development — whether antigens, antibodies, or calibrator proteins — you've almost certainly encountered proteins produced in CHO cells. CHO stands for Chinese Hamster Ovary cells, and they are the workhorse of the biopharmaceutical industry.
Over 70% of approved therapeutic proteins globally are produced in CHO cells. From monoclonal antibodies to cytokines to vaccine antigens, CHO-based expression is the gold standard for proteins that require proper folding, post-translational modification, and batch-to-batch consistency.
But what exactly makes CHO cells so special? And what do IVD assay developers need to know when selecting CHO-expressed proteins? This guide breaks it all down.
1. What Is a CHO Cell?
CHO cells are epithelial cells derived from the ovary of the Chinese hamster (Cricetulus griseus). They were first isolated in the 1950s by Dr. Theodore Puck and have since been adapted for laboratory and industrial use as a mammalian cell host for recombinant protein production.
Unlike bacterial systems (like E. coli) or yeast (like Pichia pastoris), CHO cells are mammalian cells. This means they have the cellular machinery to perform complex post-translational modifications — most importantly, glycosylation — that are critical for the biological activity and stability of many proteins.
Key Fact
CHO cells are classified as a non-tumorigenic cell line, making them safer for large-scale biopharmaceutical production compared to some other mammalian expression systems.
Key components: ER stress sensors (CHOP, PERK, BiP), HsQSOX1b-mediated disulfide bond formation in the ER lumen, and Survivin-mediated apoptosis inhibition enabling high-density culture. These pathways collectively determine recombinant antibody folding efficiency and secretion yield in CHO expression systems.
Source: Zhang et al., Cells 2024, 13(17), 1481 (CC BY 4.0)
2. Why CHO Dominates Biopharmaceutical Production
Several technical and practical advantages make CHO cells the preferred expression host for recombinant proteins in the diagnostics and pharmaceutical industries:
2.1 Human-Compatible Glycosylation
CHO cells add N-linked glycosylation to recombinant proteins that closely resembles human glycosylation patterns. This is critical for:
- Antigenicity: Proteins with human-like glycans are less likely to trigger unwanted immune responses in patients or interfere with assay antibodies.
- Protein stability: Proper glycosylation improves protein folding, thermal stability, and resistance to proteolytic degradation.
- Effector function: For therapeutic antibodies, glycosylation directly affects ADCC (antibody-dependent cellular cytotoxicity) activity.
2.2 High-Yield, Scalable Production
Modern CHO cell lines can achieve gram-per-liter expression levels in bioreactors. Industrial-scale CHO culture is well-established, with robust protocols for:
- Suspension culture in chemically defined media
- High-density perfusion and fed-batch bioreactors
- Single-use bioreactor systems for flexible manufacturing
2.3 Proven Safety & Regulatory Track Record
CHO cells have an extensive regulatory history with FDA, EMA, and NMPA. Thousands of CHO-produced biologics have been approved, making them a well-characterized and accepted platform for both pharmaceutical and IVD applications.
2.4 Stable Cell Line Development
CHO cells can be engineered to produce stable, clonal cell lines with consistent expression over hundreds of generations. This enables:
- Long-term production consistency (critical for lot-to-lot reproducibility)
- High-throughput screening of high-producing clones
- Flexibility to switch between serum-free and defined media
"CHO cells represent the intersection of human-like protein quality, industrial scalability, and regulatory acceptance — a combination no other expression system can match."
3. Glycosylation: The Key Advantage
Glycosylation — the enzymatic addition of sugar chains (glycans) to proteins — is the most complex and biologically significant post-translational modification performed by CHO cells.
3.1 N-Linked vs. O-Linked Glycosylation
CHO cells primarily perform N-linked glycosylation, where sugar chains are attached to asparagine (Asn) residues in the sequence motif Asn-X-Ser/Thr. O-linked glycosylation also occurs but is less predictable.
3.2 Glycan Structure and Function
The glycan structures added by CHO cells include:
- High-mannose: Common in viral envelope proteins; recognized by immune receptors
- Complex biantenary: Most common in CHO-produced antibodies; two antennae with terminal galactose and sialic acid
- Core fucosylation: CHO cells naturally add core fucose to N-glycans, which affects antibody effector functions
- Sialylation: Terminal sialic acid residues improve serum half-life by reducing clearance
3.3 Why Glycosylation Matters for IVD
For diagnostic assay development, glycosylation directly impacts:
- Epitope recognition: Proper glycosylation preserves the native epitope structure recognized by diagnostic antibodies
- Protein stability: Glycosylated antigens are more stable in storage and less prone to aggregation
- Specificity: Non-human glycosylation (e.g., from insect cells or plant systems) can create background signal in human immunoassays
IVD Application Note
When selecting recombinant antigens for immunoassay development, always verify the expression system. CHO-expressed antigens offer the most human-relevant glycosylation profile, minimizing non-specific binding and maximizing assay performance in clinical samples.
4. How CHO Expression Works
The general workflow for producing a recombinant protein in CHO cells involves several stages:
Step 1: Gene Construction
The gene encoding the target protein is cloned into an expression vector containing:
- A strong mammalian promoter (e.g., CMV, EF-1α)
- Selectable marker genes (e.g., glutamine synthetase / GS system, DHFR)
- Polyadenylation signals for mRNA stability
Step 2: Cell Line Development
The expression vector is introduced into CHO cells via:
- Transfection: Electroporation, lipofection, or viral transduction
- Selection: Only cells that have taken up the vector survive in selection media
- Cloning: Single cells are isolated and screened for high producers
Stage 1 — Transfection: Expression vector (containing antibody gene + selection marker) is introduced into CHO host cells via electroporation or lipofection.
Stage 2 — Selection: Cells are cultured in selection media (e.g., MSX for GS system); only stable integrants survive.
Stage 3 — Single-cell cloning: High-producing clones are isolated by limiting dilution or FACS sorting.
Stage 4 — Clone evaluation: Productivity, growth kinetics, and product quality are assessed.
Stage 5 — Cell banking: Lead clone is expanded and cryopreserved as Master and Working Cell Banks.
Adapted from industry-standard CHO expression protocols (ICH Q5D).
Step 3: Process Development & Scale-Up
Once a high-producing clone is selected, the process is scaled up through:
- Seed train: Progressive expansion from shake flasks to bioreactors
- Bioreactor culture: Fed-batch or perfusion mode at controlled pH, temperature, and dissolved oxygen
- Harvest: Clarified culture supernatant containing the secreted protein
Step 4: Purification & QC
The recombinant protein is purified from the culture supernatant using a combination of:
- Protein A/G chromatography (for antibodies)
- Ion exchange chromatography (IEX)
- Size exclusion chromatography (SEC)
- Viral inactivation and filtration steps
5. Common CHO Expression Platforms
Several commercial CHO platforms are widely used for recombinant protein production:
| Platform | Selection System | Key Features |
|---|---|---|
| CHO-K1 | Host cell line (non-transfected) | Original CHO lineage; widely available; high transfection efficiency |
| CHO-S | Suspension-adapted CHO-K1 | Grown in suspension culture; ideal for scalable bioreactor production |
| CHO-DG44 | DHFR knockout (methotrexate amplification) | Enables gene amplification; high-yield production of complex proteins |
| CHO-GS | Glutamine synthetase knockout (MSX selection) | Industry-standard for stable, high-yield monoclonal antibody production |
| ExpiCHO | Transient + stable expression | High-density suspension culture; transient expression in 7–14 days |
6. CHO-Produced Proteins in IVD Development
For IVD reagent developers, CHO-expressed proteins offer several practical advantages:
6.1 Recombinant Antigens
CHO-expressed recombinant antigens provide:
- Native conformation: Proper folding and glycosylation preserve conformational epitopes recognized by patient antibodies in serological assays
- Low endotoxin: CHO culture systems produce very low levels of bacterial endotoxins compared to E. coli
- High purity: Chromatographic purification yields high-purity antigens with consistent quality
6.2 Monoclonal Antibodies
Most IVD monoclonal antibodies — including those used as capture and detection reagents in ELISA, CLIA, and lateral flow — are produced in CHO cells because:
- Their glycosylation profile is human-compatible, reducing background in clinical samples
- CHO-produced antibodies have consistent subclass distribution (IgG1, IgG4, etc.)
- They are compatible with protein A purification and conjugation chemistry
6.3 Reference Standards & Calibrators
CHO-expressed proteins used as assay calibrators and reference standards benefit from:
- Batch-to-batch consistency across production runs
- Long-term stability when properly formulated
- Traceability to well-characterized CHO cell banks
7. Limitations and Considerations
While CHO cells are the gold standard, they are not without trade-offs:
| Consideration | Impact | Mitigation |
|---|---|---|
| Higher cost vs. bacterial/yeast systems | More expensive production; longer timelines (weeks vs. days) | Reserve CHO for high-value, quality-critical proteins |
| Glycan heterogeneity | CHO cells produce a mix of glycan structures; not all identical to human | Cell line engineering (e.g., knock-out of fucosyltransferases) |
| Lower sialylation than human cells | Reduced serum half-life for some therapeutic applications | Engineered cell lines with enhanced sialylation capacity |
| Risk of viral contamination | CHO cells can harbor endogenous retroviruses | Viral inactivation steps (low pH, solvent/detergent); regulatory testing required |
For IVD applications specifically, these limitations are generally manageable. The quality and performance advantages of CHO-expressed proteins almost always outweigh the additional cost and complexity.
8. Summary
CHO cell expression systems are the undisputed leader in recombinant protein production for diagnostics and biopharmaceuticals. Here's what IVD developers need to remember:
- CHO cells provide human-compatible glycosylation — the most important advantage over bacterial and yeast expression systems
- Properly glycosylated antigens preserve conformational epitopes, reduce non-specific binding, and improve assay performance in clinical samples
- Industrial-scale CHO production is well-established and regulatory-approved, ensuring consistent supply for commercial IVD kits
- For assay calibration and reference standards, CHO-expressed proteins offer unmatched batch-to-batch consistency
- Know your expression system — the difference between CHO, insect cell, and prokaryotic expression has real implications for your assay's analytical performance
"When the quality of your recombinant antigen or antibody determines whether a clinician gets the right result — CHO is almost always the right choice."
At Sekbio, all of our recombinant antigens and monoclonal antibodies for IVD use are produced in well-characterized mammalian cell systems. If you're developing a diagnostic assay and want to discuss the right expression platform for your target protein, reach out to our technical team.
Frequently Asked Questions
What is a CHO cell expression system?
A CHO (Chinese Hamster Ovary) cell expression system uses mammalian cells to produce recombinant proteins from a cloned gene inserted via an expression vector. After transfection and selection of stable clones, cells are scaled up in bioreactors. CHO cells perform human-compatible glycosylation, disulfide bond formation, and correct protein folding — making them the industry standard for biologics and IVD reagent production.
Why are CHO cells preferred for IVD recombinant protein production?
CHO cells dominate IVD protein production because they produce human-compatible glycosylation patterns that minimize non-specific binding in clinical samples, have an extensive regulatory track record with FDA, EMA, and NMPA, and enable scalable bioreactor production with gram-per-liter yields. Over 70% of approved therapeutic proteins globally are produced in CHO cells.
How does CHO cell glycosylation affect IVD assay performance?
CHO cells add complex biantennary N-linked glycans with terminal galactose and sialic acid closely resembling human glycosylation. This preserves conformational epitopes recognized by diagnostic antibodies, improves protein stability, and reduces non-specific background in patient serum. Non-human glycosylation from insect cells or bacteria can create false signals in human immunoassays.
What is the difference between CHO-DG44, CHO-GS, and ExpiCHO platforms?
CHO-DG44 uses DHFR knockout with methotrexate gene amplification for high-yield stable production. CHO-GS uses glutamine synthetase knockout with MSX selection — the industry standard for commercial monoclonal antibody manufacturing. ExpiCHO is a high-density suspension system optimized for fast transient expression (7–14 days) for early-stage protein screening. The right platform depends on timeline, yield requirements, and regulatory needs.
How long does it take to develop a stable CHO cell line?
A typical stable CHO cell line development timeline is 8–16 weeks: gene construction and transfection (2–4 weeks), selection and clonal expansion (4–6 weeks), clone screening (2–4 weeks), and cell banking (1–2 weeks). Transient CHO expression can deliver initial protein in 7–14 days — useful for early characterization before committing to stable line development.
Can Sekbio develop stable CHO cell lines and produce recombinant antibodies for IVD?
Yes. Sekbio develops stable CHO and HEK293 cell lines for recombinant monoclonal antibody and antigen production targeting IVD applications. Services include gene synthesis, vector construction, cell line development, and ISO 13485-certified GMP-grade purification with full lot traceability. Visit our Antibody Development Services page to discuss your project's requirements and timelines.